Drugs / ASP9831
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00668070 | Apr 2008 → Oct 2010 | metabolic dysfunction-associated steatohepatitis | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP9831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00668070 ↗ |
| Action | Inhibit | “PDE4 Inhibitor ASP9831” NCT00668070 ↗ |
| Modality | Small molecule | — CHEMBL6068540 ↗ |
| Route | Oral | “Oral” NCT00668070 ↗ |